HUB Organoids in Financial Times

December 10, 2019. Yesterday the Financial Times featured an article on Organoid Innovation:

Organoid innovation offers potential for cancer research.

“Organoids have become one of the fastest growing fields in biomedical research over the past decade”

Prof Clevers: “We set up a non-profit foundation called Hubrecht Organoid Technology [HUB], which holds my lab’s patents. In addition to carrying out research, HUB offers licences for drug screening and access to organoids in its biobanks for pre-clinical drug discovery and validation.”

Pharmaceutical companies are using organoids derived from specific tumours to screen potential cancer drugs. A wide range of tissues are available for applications ranging from drug discovery to personalised medicine.

September 04, 2020 HUB and BGI-Qingdao sign a Memorandum of Unde... Utrecht and Qingdao, Sep 4th, 2020 – Hubrecht Organoid Technology (HUB) and BGI-Qingdao announced today that they ... read more
May 27, 2020 Studying the development of ovarian cancer wi... read more
May 26, 2020 HUB Patient-Derived Organoids added to CrownB... read more